Bovine Respiratory Disease Treatment Market
Bovine Respiratory Disease Treatment Market (Treatment Type - Vaccines, Antibiotics, NSAIDs, and Immunomodulators; Disease Type - Upper Respiratory Tract Infections, Pneumonia (Lower Respiratory Tract Infection), and Diphtheria; Distribution Channel - Veterinary Hospitals, Veterinary Clinics, Private Veterinary Pharmacies, and Veterinary Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
Press Release :
Global Bovine Respiratory Disease Treatment Market: Snapshot
Bovine respiratory disease (BRD) is a commonly occurring respiratory disorder among cattle, which may result from a single or a number of factors combined. The disease has been gaining much attention of late as it significantly impacts the global beef industry. As a result, the prevention as well as treatment of bovine respiratory disease is necessary in order to mitigate its impact on animal production and the overall beef industry.
The bovine respiratory disease treatment market is projected to expand at a strong pace in terms of revenue in the coming years, thanks to rising consumption of animal protein among the human population, increasing cattle population, and a number of environmental factors. Transparency Market Research finds that the global market for bovine respiratory disease treatment will grow from US$805.9 mn in 2015 to US$1543.9 mn by 2024, and projected to expand at a CAGR of 7.6% therein.
Veterinary Hospitals Account for Dominant Share in Bovine Respiratory Disease Treatment Market
By way of disease type, upper respiratory tract infections held the leading share in the global bovine respiratory disease treatment market in terms of revenue in 2015. The key causative agents of upper respiratory tract infections include infectious m.haemolytica, bovine rhinotracheitis, and type 1 bovine herpesvirus. Diphtheria and lower respiratory tract infection, or pneumonia, also accounted for a prominent share that year.
Based on distribution channel, the global bovine respiratory disease treatment market includes veterinary clinics, veterinary hospitals, veterinary research institutes, and private veterinary pharmacies. Veterinary hospitals dominated the market in 2015 in terms of revenue owing to factors such as increasing population of bovine, which is likely to increase the chances of respiratory diseases among cattle. Moreover, since most of the procedures are carried out in veterinary hospitals, this segment will continue to gain much traction.
Also exhibiting strong potential during the course of the forecast period is the private veterinary pharmacies segment, which is projected to register a significant CAGR through 2024, especially in most of the emerging parts of the world. In addition to this segment, the veterinary research institutes and veterinary clinics segments will also grow steadily.
Powered by U.S., North America Leads Global Market
From a geographical point of view, the bovine respiratory disease treatment market has been segmented into: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America accounts for a major share in the global market, of which around 90% is held by the U.S. alone. The bovine respiratory disease treatment market in the U.S. is propelled by the rising domestic production, consumption, and export of bovine meat.
Europe has also been a major contributor to this market and is fueled by the growing prevalence of several causative agents for respiratory diseases among bovines, rapidly changing environmental factors, and expanding cattle population, which is driven by the rising demand for better quality bovine meat and products. Asia Pacific is likely to emerge as a highly lucrative market for bovine respiratory disease treatment as it is the leading producer of bovine livestock. The market in Asia Pacific is projected to expand at a CAGR of 8.2% from 2016 to 2024, with the demand for bovine respiratory disease treatment products significantly high in China, India, and Australia.
Bayer AG, Elanco, Vetoquinol, Merial, Zoetis Services LLC, Ceva, Boehringer Ingelheim GmbH, Merck & Co., Inc., Bimeda Animal Health, and Virbac Group are some of the top companies in this space. Despite the fact that there are a large number of players operating in the global bovine respiratory disease treatment market, the vendor landscape is highly consolidated and this has resulted in a high degree of competition.
Global Bovine Respiratory Disease Treatment Market: Overview
Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.
Moreover, according to the World Bank Group (2016), global human population is estimated to be 7.4 billion in 2016 and is growing at a rate of 1.8% per year. Hence, demand for beef has increased due to rising population and increasing disposable income across the world. The rising demand for high quality bovine derived products is influencing the bovine respiratory disease treatment market. Despite of innovations in veterinary medicines and advancement in technology, bovine respiratory disease is the leading cause to impact negatively on both the dairy and beef industries due to calf mortality, additional labor cost and treatment expenses. Moreover, bovine respiratory disease affects adversely on reproductive performance, growth and longevity of cattle. Hence, prevention and treatment of bovine respiratory disease have become important to decrease the impact on animal production and the beef industry. Therefore, the bovine respiratory disease treatment market is anticipated to witness significant growth in terms of revenue during the forecast period.
Global Bovine Respiratory Disease Treatment Market: Segmentation
In terms of treatment type, the bovine respiratory disease treatment market has been categorized into vaccines, antibiotics, NSAIDs, and immunomodulators. Causative agents such as viruses leading to bovine respiratory disease have no direct treatment. Hence, vaccination is the preferred choice of preventive action against the disease. This increase market potential for vaccines. However, virus infected cattle is exposed to bacteria, parasites, and various other factors. Therefore, antibiotics are the preferred choice of treatment for bovine respiratory diseases. Effective treatment and significant demand has increased the scope for antibiotics in the bovine respiratory disease treatment market.
However, according to NCBI report, combination treatment with anti-inflammatory drugs such as NSAIDs has better results over the monotherapy of antibiotics. This has led to increase in usage of NSAIDs in bovine respiratory disease treatment. Bovine respiratory disease is generally treated with several combination therapies. However, growing resistance to antibiotics and drying pipeline has increased demand for novel treatment options for which cattle do not develop resistance, and consequently there is no impact on human life.
Development of newer generation antibiotics for cattle is anticipated to drive the global bovine respiratory disease treatment market during the forecast period. In order to avoid the issue of antibiotics resistance in bovine population, preventive measures such as vaccination and immunomodulators has observed increased global acceptance against the bovine respiratory disease. Hence, preventive treatment is gaining momentum due to growing awareness about the negative impact of antibiotics on human health. This has driven the market for immunomodulators, vitamin injections, and other immunity building products.
In terms of disease type, the market has been segmented into upper respiratory tract infections, diphtheria, and pneumonia (lower respiratory tract infection). Upper respiratory tract infections dominated the global bovine respiratory disease market, accounting for significant share in terms of revenue in 2015. Respiratory infections first affect the upper respiratory tract, which is also the most vulnerable region, followed by other parts of the respiratory tract. Diphtheria accounted for significant share of the bovine respiratory disease treatment market in 2015. Pneumonia (lower respiratory tract infection) accounted for high market share, followed after upper respiratory tract infection in 2015. Hence, early detection of infection is important in bovine respiratory diseases treatment.
In terms of distribution channel, the global bovine respiratory disease treatment market has been segmented into veterinary hospitals, veterinary clinics, private veterinary pharmacies, and veterinary research institutes. Veterinary hospitals dominated the global bovine respiratory disease market in 2015. The segment dominated the market due to factors such as rising population of cattle which increases prevalence of bovine respiratory diseases. The private veterinary pharmacies distribution channel segment is projected to register significant CAGR during the forecast period. The segment is likely to witness strong growth in most of the emerging parts of the world and preference for medicines from private veterinary pharmacies for bovine serum respiratory diseases. However, the veterinary clinics and veterinary research institutes segments are expected to grow steadily as majority of procedures are carried out in veterinary hospitals.
Global Bovine Respiratory Disease Treatment Market: Geographical and Competitive Dynamics
Geographically, the bovine respiratory disease treatment market has been categorized in five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the major share of the global bovine respiratory disease treatment market in 2015, where the U.S. dominates the market in terms of revenue. Europe accounted for a significant share of the market in 2015. Changing environmental factors, growing prevalence of causative agents for respiratory disease, increasing demand for quality bovine products, and rising bovine population are the key factors driving the bovine respiratory disease treatment market in Europe. Asia Pacific is the largest producer of bovine livestock. Hence, it presents significant opportunities in the bovine respiratory disease treatment market. India and China are the key markets for bovine respiratory disease treatment, as these have largest livestock population compared to other countries across the globe. Latin America and Middle East & Africa have comparatively smaller markets for bovine respiratory disease treatment. However, Brazil, Mexico, and Argentina are the emerging markets in Latin America due to significant number of livestock population.
Key players operating in the global bovine respiratory disease treatment market are Merck & Co., Inc., Zoetis Services LLC, Bayer AG, Elanco, Merial, Boehringer Ingelheim GmbH, Virbac Group, Ceva, Vetoquinol, and Bimeda Animal Health, among others.
The bovine respiratory disease treatment market has been segmented as follows:
Global Bovine Respiratory Disease Treatment Market, by Treatment Type
Global Bovine Respiratory Disease Treatment Market, by Disease Type
- Upper Respiratory Tract Infections
- Pneumonia (lower respiratory tract infection)
Global Bovine Respiratory Disease Treatment Market, by Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Private Veterinary Pharmacies
- Veterinary Research Institutes
Global Bovine Respiratory Disease Treatment Market, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of APAC
- Middle East & Africa
- Saudi Arabia
- South Africa
- North Africa
- Rest of MEA
- Latin America
- Rest of Latin America